gabapentin has been researched along with ALS - Amyotrophic Lateral Sclerosis in 16 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We designed a phase II trial to evaluate the efficacy of gabapentin in slowing the rate of decline in muscle strength of patients with amyotrophic lateral sclerosis (ALS) and to assess safety and tolerability." | 9.08 | Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. ( Armon, C; Barohn, RJ; Bromberg, MB; Bryan, WW; Gelinas, DF; Mendoza, MC; Miller, RG; Moore, D; Neville, HE; Parry, GJ; Petajan, JH; Ravits, JM; Ringel, SP; Ross, MA; Young, LA, 1996) |
| "To provide the biochemical rationale for the use of the new anticonvulsant agent gabapentin as a treatment for amyotrophic lateral sclerosis (ALS)." | 7.69 | Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. ( Rothstein, JD; Schielke, GP; Welty, DF, 1995) |
| "Gabapentin is a modulator of the glutamatergic system and has been shown to prolong survival in the transgenic model of familial ALS." | 6.69 | The natural history and the effects of gabapentin in amyotrophic lateral sclerosis. ( Balzarini, C; Brigatti, M; Comazzi, F; Mazzini, L; Mora, G; Pastore, E; Pirali, I, 1998) |
| "We designed a phase II trial to evaluate the efficacy of gabapentin in slowing the rate of decline in muscle strength of patients with amyotrophic lateral sclerosis (ALS) and to assess safety and tolerability." | 5.08 | Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. ( Armon, C; Barohn, RJ; Bromberg, MB; Bryan, WW; Gelinas, DF; Mendoza, MC; Miller, RG; Moore, D; Neville, HE; Parry, GJ; Petajan, JH; Ravits, JM; Ringel, SP; Ross, MA; Young, LA, 1996) |
| "To provide the biochemical rationale for the use of the new anticonvulsant agent gabapentin as a treatment for amyotrophic lateral sclerosis (ALS)." | 3.69 | Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis. ( Rothstein, JD; Schielke, GP; Welty, DF, 1995) |
| "Gabapentin is a modulator of the glutamatergic system and has been shown to prolong survival in the transgenic model of familial ALS." | 2.69 | The natural history and the effects of gabapentin in amyotrophic lateral sclerosis. ( Balzarini, C; Brigatti, M; Comazzi, F; Mazzini, L; Mora, G; Pastore, E; Pirali, I, 1998) |
| "The first clinical trials in spinal muscular atrophy are currently underway." | 2.40 | Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases. ( Miller, RG, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (62.50) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armon, C | 2 |
| Kalra, S | 1 |
| Cashman, NR | 1 |
| Caramanos, Z | 1 |
| Genge, A | 1 |
| Arnold, DL | 1 |
| Miller, RG | 5 |
| Moore, DH | 2 |
| Jackson, CE | 1 |
| Cory, PR | 1 |
| Gidal, Be | 1 |
| Welty, DF | 1 |
| Schielke, GP | 1 |
| Rothstein, JD | 1 |
| Romano, JG | 1 |
| Moore, D | 1 |
| Young, LA | 1 |
| Barohn, RJ | 2 |
| Bromberg, MB | 1 |
| Bryan, WW | 1 |
| Gelinas, DF | 2 |
| Mendoza, MC | 1 |
| Neville, HE | 1 |
| Parry, GJ | 1 |
| Petajan, JH | 1 |
| Ravits, JM | 1 |
| Ringel, SP | 1 |
| Ross, MA | 1 |
| Gurney, ME | 1 |
| Cutting, FB | 1 |
| Zhai, P | 1 |
| Doble, A | 1 |
| Taylor, CP | 2 |
| Andrus, PK | 1 |
| Hall, ED | 1 |
| Mazzini, L | 1 |
| Mora, G | 1 |
| Balzarini, C | 1 |
| Brigatti, M | 1 |
| Pirali, I | 1 |
| Comazzi, F | 1 |
| Pastore, E | 1 |
| Forshew, DA | 1 |
| Caramia, MD | 1 |
| Palmieri, MG | 1 |
| Desiato, MT | 1 |
| Iani, C | 1 |
| Scalise, A | 1 |
| Telera, S | 1 |
| Bernardi, G | 1 |
| McDermott, MP | 1 |
| Rowland, LP | 1 |
| Dronsky, V | 1 |
| Mendoza, M | 1 |
| Bryan, W | 1 |
| Ravits, J | 1 |
| Yuen, E | 1 |
| Neville, H | 1 |
| Ringel, S | 1 |
| Bromberg, M | 1 |
| Petajan, J | 1 |
| Amato, AA | 1 |
| Jackson, C | 1 |
| Johnson, W | 1 |
| Mandler, R | 1 |
| Bosch, P | 1 |
| Smith, B | 1 |
| Graves, M | 1 |
| Ross, M | 1 |
| Sorenson, EJ | 1 |
| Kelkar, P | 1 |
| Parry, G | 1 |
| Olney, R | 1 |
| Brigell, MG | 1 |
4 reviews available for gabapentin and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Anticonvulsants; Clinical Trials as Topic; Cyclohex | 1999 |
Potential use of gabapentin and lamotrigine.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Anticonvulsants; Clinical Trials as Topic; Cyclohex | 1995 |
Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases.
Topics: Acetates; Adolescent; Adult; Amines; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrop | 1999 |
Therapeutic advances: new hope for patients with ALS.
Topics: Acetates; Aged; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarboxylic Acids; GABA Agonists; G | 1998 |
4 trials available for gabapentin and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group.
Topics: Acetates; Adult; Aged; Amines; Amyotrophic Lateral Sclerosis; Anticonvulsants; Cyclohexanecarboxylic | 1996 |
The natural history and the effects of gabapentin in amyotrophic lateral sclerosis.
Topics: Acetates; Administration, Oral; Adult; Aged; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarbo | 1998 |
Pharmacologic reversal of cortical hyperexcitability in patients with ALS.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Cerebral Cortex; Cyclohexanecarboxylic Acids; Diaze | 2000 |
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarboxylic Acids; Double-Blind Method; F | 2001 |
8 other studies available for gabapentin and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy.
Topics: Acetates; Aged; Amines; Amyotrophic Lateral Sclerosis; Aspartic Acid; Cell Survival; Creatine; Cyclo | 2003 |
Western ALS Study Group.
Topics: Amines; Amyotrophic Lateral Sclerosis; Calcium Channel Blockers; Ciliary Neurotrophic Factor; Clinic | 2004 |
Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis.
Topics: Acetates; Amines; Amino Acids, Branched-Chain; Amyotrophic Lateral Sclerosis; Anticonvulsants; Brain | 1995 |
Reduction of fasciculations in patients with amyotrophic lateral sclerosis with the use of gabapentin.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Anticonvulsants; Cyclohexanecarboxylic Acids; Fasci | 1996 |
Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Animals; Brain; Cyclohexanecarboxylic Acids; Diet; | 1996 |
New approaches to therapy of amyotrophic lateral sclerosis.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Animals; Brain-Derived Neurotrophic Factor; Cyclohe | 1998 |
ALS defeats gabapentin: reflections on another failed treatment.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amin | 2001 |
ALS defeats gabapentin: reflections on another failed treatment.
Topics: Acetates; Amines; Amyotrophic Lateral Sclerosis; Cyclohexanecarboxylic Acids; Excitatory Amino Acid | 2001 |